Warner Chilcott Femtrace Launch Expected In First Quarter 2005
Warner Chilcott is planning an early 2005 launch for Femtrace following FDA approval of the hormone replacement therapy Aug. 20
You may also be interested in...
Wyeth's direct-to-consumer advertising campaign for Prempro highlights the hormone replacement therapy's lowest dose approved by FDA
FDA is recommending a hormone replacement therapy class "black box" warning on an increased risk of dementia with use of estrogen and combination estrogen/progestin products
Labeling for Galen's vaginal hormone therapy Femring follows the template established for Wyeth's Premarin family to incorporate the findings from NIH's Women's Health Initiative study